Screener
Agios Pharmaceuticals AGIO Product revenue, net — Total Revenue
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Agios Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Agios Pharmaceuticals’s 10-Q, filed July 30, 2026.
- Filed
- Jul 30, 2026, 9:56 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001439222-26-000118
| (In thousands, except share and per share data) | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenues: | ||||
| Product revenue, net | $44,745 | $12,455 | $65,491 | $21,181 |
| Total revenue | 44,745 | 12,455 | 65,491 | 21,181 |
| Operating expenses: | ||||
| Cost of sales | $2,996 | $1,702 | $4,315 | $2,787 |
| Research and development | 100,754 | 91,940 | 181,902 | 164,683 |
| Selling, general and administrative | 51,547 | 45,869 | 99,851 | 87,396 |
| Total operating expenses | 155,297 | 139,511 | 286,068 | 254,866 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Agios Pharmaceuticals's product revenue, net — total revenue?
- Agios Pharmaceuticals (AGIO) reported product revenue, net — total revenue of $44.75M in Q2 2026.
- How has Agios Pharmaceuticals's product revenue, net — total revenue changed year-over-year?
- Agios Pharmaceuticals's product revenue, net — total revenue increased by 259.3% year-over-year, from $12.46M to $44.75M.
- What is the long-term trend for Agios Pharmaceuticals's product revenue, net — total revenue?
- Over 4 years (2021 to 2025), Agios Pharmaceuticals's product revenue, net — total revenue has grown at a 10.0% compound annual growth rate (CAGR), from $36.91M to $54.03M.
- What does product revenue, net — total revenue mean?
- This metric represents the proportion of total corporate revenue derived specifically from the sale of commercialized pharmaceutical products. It serves as a key indicator of a biopharmaceutical company's transition from a research and development-focused entity to a commercial-stage business. Tracking this ratio helps investors evaluate the company's success in scaling its product portfolio relative to other income streams such as collaboration or licensing revenue.
Ask your AI about Agios Pharmaceuticals's product revenue, net — total revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude